Cellular Immunotherapy to Target WT1, Survivin and TERT for AML is under clinical development by Boryung ViGenCell and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cellular Immunotherapy to Target WT1, Survivin and TERT for AML’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cellular Immunotherapy to Target WT1, Survivin and TERT for AML overview
Cellular immunotherapy is under development for the treatment of relapsed or refractory acute myelocytic leukemia. It comprises of T cells which are modified to target Wilms tumor protein (WT1), survivin and telomerase reverse transcriptase (TERT) expressing cancer cells. It is administered through intravenous route.
Boryung ViGenCell overview
Boryung ViGenCell a healthcare company that engaged in the immune cell therapy services. The company is headquartered in Seoul, South Korea.
For a complete picture of Cellular Immunotherapy to Target WT1, Survivin and TERT for AML’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.